

LITERATURA

1. Kister I, Caminero AB, Monteith TS, et al. Migraine is comorbid with multiple sclerosis and associated with a more symptomatic MS course. *J Headache Pain*. 2010;11(5):417-425.
2. Putzki N, Pfrim A, Limonroth V, et al. Prevalence of migraine, tension-type headache and trigeminal neuralgia in multiple sclerosis. *Eur J Neurol*. 2009;16:262-267.
3. Moisset X, Ouchchane L, Guy N, et al. Migraine headaches and pain with neuropathic characteristics: comorbid conditions in patients with multiple sclerosis. *Pain*. 2013;154:2691-2699.
4. Stovner LJ, Andree C. Prevalence of headache in Europe: a review for EuroLight project. *J Headache Pain*. 2010;11(4):289-299.
5. Flachenecker P, Stuke K, Elias W, et al. Multiple sclerosis registry in Germany: results of extension phase phase 2005/2006. *Dtsch Arztebl*. 2008;105(7):113-119.
6. Gebhardt M, Kropp P, Jurgens TP, et al. Headache in the first manifestation of multiple sclerosis – prospective, multicenter study. *Brain Behav*. 2017;7(12):e00852. <https://doi.org/10.1002/brb3.852>.
7. Gebhardt M, Kropp P, Hoffmann F, et al. Kopfschmerzen bei Multiplex Sklerose. *Nervenarzt*. 2020;91(10):926-935.
8. Saberi A. Migraine headache in Multiple Sclerosis. Is more frequent among MS patients? *Romanian journal of neurology*. 2023;22(1):54-57.
9. Kister I, Caminero A, Herbert J, et al. Tension-type headache and migraine in multiple sclerosis. *Curr Pain Headache Rep*. 2010;14:441-448.
10. Mijajlovic MD, Aleksic VM, Covickovic, et al. Cluster headache as a first manifestation of multiple sclerosis: case report and literature review. *Neuropsychiatr Dis Treat*. 2014;10:2269-2274.
11. Montano N, Rapisarda A. The role of neurovascular conflict in patients with multiple sclerosis and trigeminal neuralgia. *Cephalgia*. 2021;41(13):1409-1410.
12. Husain F, Pardo G, Rabadi M. Headache and Its Management in Patients With Multiple Sclerosis. *Curr Treat Options Neurol*. 2018;20:10. DOI 10.1007/s11940-018-0495-4.
13. Stewart WF, Lipton RB, Liberman J. Variation in migraine prevalence by race. *Neurology*. 1996;47:52-59.
14. Rosali G. The prevalence of multiple sclerosis in the world: an update. *Neurol Sci*. 2001;22:117-139.
15. Kister I, Munger KL, Herbert J, et al. Increased risk of multiple sclerosis among women with migraine in the nurses health study II. *Mult Scler*. 2012;18(1):90-97.
16. Mariotti P, Nociti V, Stefanini MC, et al. Chronic migraine-like headache caused by a demyelinating lesion in the brain stem. *Pain Med*. 2012;13(4):610-612.
17. Elmazny A, Hamdy SM, Abdel-Naseer M, et al. Interferon-beta induced headache in patients with multiple sclerosis: frequency and characterization. *J Pain Res* 2020;13:537-545. <http://doi.org/10.2147/JPR.S230680>.
18. Naktsuji Y, Nakano M, Moriya M, et al. Beneficial effect of interferon-beta treatment in patients with multiple sclerosis is associated with transient increase in serum IL-6 level in response to interferon-beta injection. *Cytokine*. 2006;15(1-2):69-74.
19. Polman C, O'Connor P, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. *N Engl J Med*. 2006;354(9):899-910.
20. CAMMS 223 Trial Investigators. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. *N Engl J Med*. 2008;359(17):1786-1801.
21. Gee JR, Chang J, Dublin AB, et al. The association of brainstem lesions with migraine-like headache: an imaging study of multiple sclerosis. *Headache*. 2005;45(6):670-677.
22. Merkler D, Klinker F, Jurgens T, et al. Propagation of spreading depression inversely correlates with cortical myelin content. *Ann Neurol*. 2009;66(3):355-365.
23. Conti P, D'Ovidio C, Conti C, et al. Progression in migraine: role of mast cells and pro-inflammatory and anti-inflammatory cytokines. *Eur J Pharmacol*. 2019;844:87-94. <http://doi.org/10.1016/j.ejphar.2018.12.004>.
24. Munno I, Marinaro M, Bassi A, et al. Immunological aspects in migraine: increase of IL-10 plasma levels during attack. *Headache*. 2001;41:764-767.
25. Magliozzi R, Howell O, Reeves C, et al. A gradient of neuronal loss and meningeal inflammation in multiple sclerosis. *Ann Neurol*. 2010;477-493.
26. Bracci-Laudiero L, Aloe L, Buanne P, et al. NGF modulates CGRP synthesis in human B-lymphocytes: a possible anti-inflammatory action of NGF? *J Neuroimmunol*. 2002;123(1-2):58-65.
27. Klein M, Woehrl B, Zeller G, et al. Stabbing headache as a sign of relapses in multiple sclerosis. *Headache*. 2013;53:1159-1161.
28. Granberg T, Martola J, Kristoffersen-Wiberg M, et al. Radiologically isolated syndrome-incidental magnetic resonance imaging findings suggestive of multiple sclerosis, a systematic review. *Mult Scler*. 2013;19(3):271-280.
29. Kantarci OH, Lebrun C, Siva A, et al. Primary progressive multiple sclerosis evolving from radiologically isolated syndrome. *Ann Neurol*. 2016;79(2):288-294.
30. Okuda DT, Kantarci O, Lebrun-Frenay C, et al. Dimethyl Fumarate Delays Multiple Sclerosis in Radiologically Isolated Syndrome. *Ann Neurol*. 2023;93(3):604-614. doi: 10.1002/ana.26555. Epub 2022 Dec 10. PMID: 36401339.

37. ČESKÝ A SLOVENSKÝ NEUROLOGICKÝ SJEZD

27.–29. 11. 2024 | CLARION CONGRESS HOTEL OSTRAVA

ČESKÁ
NEUROLOGICKÁ
SPOLEČNOST

SLOVENSKÁ NEUROLOGICKÁ
SPOLEČNOST

www.registrace-solen.cz

Těšíme se na setkání s Vámi
v listopadu 2024 v Ostravě!

